Jeryl lynn strain

Vaccines to prevent measles, mumps and rubella have been available in the U.S. since the 1960s. The three vaccines were combined to form the MMR vaccine in 1971, and since the late 1970s, only one version, known as MMR II, has been used throughout the U.S. Created by Maurice Hilleman and colleagues at Merck, the MMR vaccine has been responsible for dramatic decreases in the rates of infections and deaths associated with each of these diseases. Measles was declared eliminated from the U.S. in 2000, and rubella followed in 2004. While rates of mumps decreased by 99%, it has never been declared eliminated from the U.S. because it has yet to meet the criteria — the absence of continuous disease transmission for 12 months or more — for doing so. However, in mid-2022, something changed. A new MMR vaccine, called PRIORIX, was approved for use in the U.S. PRIORIX is made by GlaxoSmithKline Biologicals. So, this month, we thought it would be useful to discuss how these vaccines compare. The active ingredients Both of the MMR vaccines contain live, weakened viruses that are similar, if not identical, and are delivered in much the same doses: • Measles component: MMR II contains the modified Enders’ Edmonston strain (Moraten) and PRIORIX contains the Schwarz strain; however, these strains are identical at the level of nucleotide sequences. • Mumps component: MMR II contains the “Jeryl Lynn” strain of mumps virus, which is composed of two lineages of the virus (JL1 and JL2). PRIORIX c...

Extract from report of GACVS meeting of 29-30 November 2006, published in the WHO Weekly Epidemiological Record on 19 January 2007 At the request of the immunization Strategic Advisory Group of Experts (SAGE), the Committee was asked to update the 2003 comprehensive review of the safety of mumps vaccine strains, paying particular attention to the risk of vaccine-derived meningitis. A review of the safety profile based on an updated literature search and data provided by some vaccine manufacturers was presented to the Committee. Similar to its previous review, 5GACVS noted that cases of aseptic meningitis and estimates of incidence rates have been reported following the use of Urabe, Leningrad–Zagreb, Hoshino, Torii, and Miyahara strains from various surveillance systems and epidemiological studies. Given the variability in the quality of these studies and in the methods used, no clear conclusion on differences in risk between these vaccine strains can be drawn. The data up to now have revealed low rates of aseptic meningitis and no cases of virologically proven meningitis following the use of Jeryl–Lynn and RIT 4385 strains. There is only limited information about the Leningrad-3 strain. No data were available to assess the safety of the S79 strain. Mass vaccination campaigns using mumps–measles–rubella vaccine that contained mumps vaccine strains associated with an increased risk of aseptic meningitis have resulted in clusters of adverse events that disrupted programmes. ...

Mumps orthorubulavirus • Mumps rubulavirus • Mumps virus The mumps virus (MuV) is the MuV replicates first by binding to the surface of cells, whereby its envelope merges with the host cell membrane to release the capsid inside of the cell. Once inside, the viral The mumps virus was first identified as the cause of mumps in 1934 and was first isolated in 1945. Within a few years after isolation, Mumps orthorubulavirus. It is assigned to the genus Characteristics [ ] Genome [ ] The mumps virus contains a nonsegmented, single-stranded, linear genome that is 15,384 nucleotides in length and made of ribonucleic acid (RNA). The genome has negative sense, so mRNA can be transcribed directly from the genome. Mumps virus encodes seven genes in the following order: • nucleocapsid (N) protein, • V/P/I (V/phospho-(P)/I) proteins, • matrix (M) protein, the most abundant protein in virions, • fusion (F) protein, • small hydrophobic (SH) transmembrane protein, • • the large (L) protein, which combines with the P protein to form the RNA-dependent RNA polymerase (RdRp). RdRp acts as both a The SH protein is thought to be involved in blocking NF(α)-mediated apoptosis of the host cell, which is done as an antiviral response to suppress the spread of viruses, though SH is not necessary for replication since MuVs engineered without SH are still able to replicate. The V protein is also involved in evading host antiviral responses by means of inhibiting production and signalling of Structure [ ...

• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • The Journal of Immunology • ImmunoHorizons • ImmunoHorizons Call for Education Papers • AAI Newsletter • • • • • • • • • • • • • • • Canister by Charles Richter and John Emrich December 2021, p. 43 Seed stock canister for Jeryl Lynn Strain National Museum of American HistoryThis unassuming stainless-steel canister played a crucial role in saving millions upon millions of children from the effects of mumps. It was one of five vessels that held the seed stock for the Jeryl Lynn strain of mumps virus used to produce over three billion doses of vaccine. The Jeryl Lynn strain was named after the daughter of Five-year-old Jeryl Lynn woke her father up at 1:00 a.m. on March 23, 1963, complaining of swelling and pain in her throat. Hilleman quickly diagnosed mumps, then drove to his laboratory at Merck to retrieve cotton swabs and nutrient broth. He took these supplies home, swabbed Jeryl Lynn’s throat, and returned the sample to his lab. Hilleman attenuated the mumps virus by repeatedly passing it through chicken embryo cells. In 1966, one of the first children to receive a dose of the experimental vaccine was Jeryl Lynn’s own sister, Kirsten. Later, the seed stock for the Jeryl Lynn strain was placed in five 15-liter canisters for safe storage. By 2015, howev...